Expert Interview
Looking at Spruce Biosciences’ Long-Term Data on Tralesinidase Alfa (TA-ERT) in Sanfilippo Syndrome Type B
Ticker(s): SPRBInstitution: University Medical Center Hamburg-Eppendorf (UKE) and International Center for Lysosomal Disorders / European Study Group on Lysosomal Diseases (ESGLD)
- Head of the Lysosomal Disease Unit and Principal Investigator at the International Center for Lysosomal Disorders at UKE and Working Group Leader of the European Study Group on Lysosomal Diseases (ESGLD)
- Manages dozens of patients with San Fillipino Syndrome and other lysosomal diseases
- Senior physician and medical specialist in Pediatrics and Youth Medicine with a clinical focus on rare metabolic and lysosomal storage disorders, including mucopolysaccharidoses, Sanfilippo syndrome, and other inherited metabolic conditions
How many patients do you manage with Sanfilippo Syndrome Type B?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for Spruce Biosciences’ Tralesinidase Alfa (TA-ERT) as a potential treatment for Sanfilippo Syndrome Type B?
Added By: lilly_adminwhat % of older patients that have progressed might not take this ERT? What prevalence of patients and what % of this disease will you think take this ERT in the US?
Added By: user1a9v3vo5Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
